Figure 6.
Experiment 3: The effect of CB1 antagonist (AM251 1 mg kg−1 and rimonabant 10 mg kg−1; both i.p.) treatment upon harmaline (30 mg kg−1; i.p.) induced symptoms. (A) Time spent on rotarod apparatus and (B) gripping time in the wire grip test. Results from the same treatment in the gait analysis test are shown as (C) hind paw stride width (cm), (D) right hind paw stride length (cm) and (F) left hind paw stride length (cm). Data for time on rotarod apparatus, gripping time in the wire grip test and right and left hind paw stride lengths were normally distributed and are represented as mean ± SEM. Hind paw stride width data were not normally distributed and are represented as medians with interquartile ranges as a box and maxima/minima as whiskers. * P < 0.05, significantly different from the harmaline only group. Numbers in parentheses indicate group sizes. No data points were excluded as outliers in the presented analyses.